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introduction
Cutaneous lymphomas (CL) are the second most common
extranodal non-Hodgkin’s lymphomas. Their incidence is
estimated at 1/100 000 yearly. Primary CL develop by definition
in the skin and remain confined to the skin for a long period of
time, while secondary CL reflect cutaneous spread from
disseminated primary nodal or extranodal lymphomas. Primary
CL include a wide spectrum of clinically and histologically
heterogeneous lymphoproliferative neoplasms: 75% of CL are
cutaneous T-cell lymphomas (CTCL); 25% cutaneous B-cell
lymphomas (CBCL); and a few percent other uncommon
forms. CL and nodal or extracutaneous lymphomas with the
same cytomorphology may differ greatly in regard to clinical
features, therapy and prognosis (Table 1).
diagnosis
The diagnosis of CL requires extensive clinical experience and
relies upon a detailed history, clinical observation, histologic
analysis (including the appropriate immunohistochemical
studies based on the working diagnosis) and proof of clonality
in lesional skin [suspected Sezary syndrome (SS): in the
peripheral blood]. Other extranodal manifestations should be
also excluded. However, many inflammatory skin diseases may
reveal clonality, as detected by PCR.
staging
Recently, the ISCL and EORTC published a new TNM staging
system for MF/SS. This classification is less helpful for CTLC
other than mycosis fungoides (MF)/SS.
therapy
Especially MF/SS are indolent neoplasms with a very wide
variation in clinical presentation. In the early stages, they affect
the quality of life due to their impact on skin appearance and
annoying symptoms such as pruritus. In some cases they can
already be disfiguring in early disease stages. In advanced stages,
local skin problems are accompanied by systemic immune
suppression which results in an increased risk of infections and
secondary malignancies. Some of the late-stage problems in
MF/SS patients might have been aggravated by earlier
therapeutic interventions, e.g. radiotherapy or phototherapy
may contribute to mutations that increase the proliferative
and invasive capacity of the tumor cell populations. Cytotoxic
drugs favor infectious complications. Most patients with
advanced disease may die due to secondary problems such as
infections.
MF/SS patients are mostly of advanced age and have many
concomitant diseases Thus, a realistic goal for CL treatment is
to achieve long-lasting remissions in a significant percentage of
patients with drugs that can be safely used without long-term
toxicity. Initial therapy should be skin directed. If the disease is
not sufficiently controlled, systemic biological therapy can be
added. Aggressive polychemotherapy is only justified for
advanced disease.
therapy of CTCL: mycosis fungoides, follicular
mucinosis and pagetoid reticulosis
A stage-adjusted, conservative therapeutic approach is
recommended for MF and its variants. In earlier stages, topical
treatments should be favored such as topical corticosteroids,
PUVA (psoralen plus UVA), topical cytostatic agents such as
mechlorethamine (HN2) and BCNU or radiation therapy with
electron beam or soft X-rays.
In advanced stages, the addition of total skin electron beam
therapy (TSEBT) (30 Gy) combined with chemotherapy with
various topical treatments [phototherapy and mechlorethamine
(nitrogen mustard)] has resulted in a higher response rate.
However, there were serious side-effects and no difference in
overall survival rate was observed.
In more advanced stages, combined topical and systemic
therapy is often employed; e.g. PUVA combined with systemic
retinoids or recombinant interferon-a (IFN-a).
Localized forms of MF such as pagetoid reticulosis are best
treated with radiation therapy—soft X-rays (12–20 Gy total dose
2 Gy 2 · weekly for 3–5 weeks) or electron beam (30–40 Gy)
(Table 2).
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Table 1. Cutaneous T-cell, B-cell and NK-cell lymphomas: clinic, phenotype and genotype
Diagnosis Clinical features Immune phenotype
Mycosis fungoides variants and subtypes Patches and plaques, later tumors CD3+, CD4+, CD45R0+, CD8– rarely, CD4–, CD8+
Folliculotropic MF Follicular mucinosis, alopecia
Pagetoid reticulosis Solitary, often hyperkeratotic, patch or plaque
Granulomatous slack skin Circumscribed areas of initially, diffusely infiltrated, later
on slack skin, typically in groins and axillae.
Se´zary syndrome Erythroderma; hyperkeratosis of palms and soles,
lymphadenopathy, alopecia.
CD3+, CD4+, CD45R0+, CD8–
Primary cutaneous CD30-positive
lymphoproliferative disorders
CD3+ or CD3–, CD4+, CD30+, frequent expression of
cytotoxic proteins, CD8+ cases possible.
Primary cutaneous anaplastic large cell lymphoma Solitary to localized nodules and tumors with or without
ulceration, sometimes spontaneous regressions.
Lymphomatoid papulosis Papular and papulonecrotic skin lesions that may ulcerate
during regression, and may heal with a superficial scar.
Subcutaneous panniculitis-like T-cell lymphoma Solitary or multiple subcutaneous nodules to indurated
plaque-like lesions
CD3+, CD4–, CD8+, cytotoxic proteins, typically TCRab+
(betaF1+), CD56–
Extranodal NK/T-cell lymphoma, nasal type Mid-facial destructive tumor; multiple plaques and
tumors on trunk and extremities
CD2+, CD56+, cytoplasmic CD3, cytotoxic proteins, no
surface CD3; EBV !
Primary cutaneous peripheral T-cell lymphoma, unspecified
Primary cutaneous aggressive epidermotropic CD8+ T-cell
lymphoma (provisional)
Mostly disseminated eruptive patches, plaques and
nodules with erosions, ulceration and necrosis
TCRb+, CD3+, CD8+, cytotoxic protein+, CD45RA+,
CD45R0–, CD4–, CD5–, CD7+/–, EBV–
Cutaneous c/d T-cell lymphoma (provisional) Dissiminated plaques and ulcero-necrotic nodules.
Involvement of mucosal membranes
TCRb–, CD3+, CD2+, CD5–, CD7+/–, CD56+, TCRd+
Primary cutaneous CD4+ small/medium-sized pleomorphic
T-cell lymphoma (provisional)
Solitary or few plaques or tumors CD3+, CD4+, CD8–, CD30–
Precursor hematologic neoplasm Typically multiple nodules and tumors, often
bruise like aspect
CD4+, CD56+, CD8–, CD7+/–, CD45RA+, CD123+ BDCA1+
CD4+/CD56+ hematodermic neoplasm (formerly blastic
NK-cell lymphoma)
Cutaneous B-cell lymphomas
Primary cutaneous marginal zone B-cell lymphoma Multiple red papules plaques or nodules CD20+, CD79a+, BCL2+, BCL6– (marginal zone B-cells)
Primary cutaneous follicle center lymphoma Solitary or grouped plaques and tumors CD20+, CD79a+, BCL6+, BCL2–, CD10+/–, MUM-1–, FoxP1–
Primary cutaneous diffuse large B-cell lymphoma, leg type Red to bluish-red tumors (legs, in elderly patients) CD20+, CD79a+, BLC2+, BCL6+, MUM-1+, FoxP1+
Primary cutaneous intravascular large B-cell lymphoma Net-like reddish patches and plaques CD20+, CD79a+
TCR, T-cell receptor; Ig, Immunoglobulin gene.
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Table 2. Therapy recommendations for MF, MF variants and pagetoid reticulosis (level of evidence III)
Stage Recommended therapy
First line
Second line Comments
IA Watch and wait Bexarotene gel (not available in Europe)
PUVA PUVA favored in Europe; UVB/TL01
(for patches)
Topical corticosteroids class III–IV
Topical HN2/BCNU
UVB/UVB narrow band
Unilesional MF;
pagetoid reticulosis
Radiation therapy (soft X-rays or electron beam,
total dose 30–40 Gy; 2 Gy 5 · weekly)
Topical PUVA These disorders represent special presentation
forms of CTCL in Stage IA
Intralesional IFN
Topical corticosteroids class III–IV
Bexarotene gel or PUVA + retinoids
IB–IIA PUVA PUVA + IFN-a
Topical HN2/BCNU Oral bexarotene
IIB PUVA + IFN-a and radiation therapy for tumors Low-dose methotrexate oral bexarotene Consider maintenance therapy with PUVA +
IFN-a or bexarotene when remission is achieved
Topical HN2/BCNU Total body electron beam
Denileukin diftitox
IIIa PUVA + IFN-a Low-dose methotrexate Consider maintenance therapy with PUVA +
IFN-a or bexarotene when remission is achieved
Topical HN2/BCNU Oral bexarotene
Extracorporeal photopheresis Total body electron beam
Chlorambucil/corticosteroids
Vorinostat
IVA PUVA + IFN-a Low-dose methotrexate Consider maintenance therapy with PUVA + IFN-a
or bexarotene when remission is achieved
Extracorporeal photopheresis Oral bexarotene
Evt. combined with IFN or methotrexate Total body electron beam
Chlorambucil/corticosteroids
Vorinostat
Low-dose long-distance (2 m) soft X-rays
IVB PUVA + IFN-a Oral bexarotene Consider maintenance therapy with PUVA + IFN-a
or bexarotene when remission is achieved
Chlorambucil/corticosteroids Gemcitabine
Liposomal doxorubicin CHOP polychemotherapy
Soft X-rays or electron beam for tumors Denileukin diftitox
Cladribine (2-chlorodeoxyadenosine)
Gemcitabine
Vorinostat
Alemtuzumab (anti-CD52)
aErythrodermic MF.
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lymphomatoid papulosis and large cell C-ALCL
Primary cutaneous CD30+ lymphoproliferative disorders have
an excellent prognosis. Both lymphomatoid papulosis (by
definition) and the nodules of large cell C-ALCL (20%) often
spontaneously regress, healing with scarring. The therapeutic
recommendations are given in Tables 3 and 4.
Se´zary syndrome (SS)
Many retrospective studies on the treatment of SS contain
inadequate information on the diagnostic criteria and staging
of the disease, making a comparison of the therapeutic options
impossible (Table 5).
therapy of CBCL: low-grade primary cutaneous
B-cell lymphoma (follicular lymphoma, marginal
zone lymphoma)
The low-grade CBCL are morphologically similar to MALT
(mucosa-associated lymphoid tissue) lymphomas and therefore
described by some authors as SALT (skin-associated lymphoid
tissue) lymphomas. The prognosis of these tumors is in general
very favorable. In those cases in which infectious agents (such
as Borrelia burgdorferi DNA) can be identified, an initial
therapeutic attempt with doxycycline (100 mg b.i.d. for 3
weeks) and assessment of the clinical response is recommended.
Distinguishing between low-grade CBCL and reactive B-cell
pseudolymphomas can be quite difficult; even clonality studies
cannot with certainty separate the two entities. Therapeutic
recommendations are given in Table 6. Rituximab should only
be employed in those cases in which CD20 expression has been
proved histologically.
large cell B-cell lymphoma
This group of CBCL has a worse prognosis than those with
follicular differentiation. There are no large studies dealing with
these tumors, making the formulation of guidelines difficult.
First-line treatments of PCLBCL leg type is R-CHOP and
radiation therapy for solitary lesions.
therapy of non-CD4+/CD56+ hematodermic
neoplasm
In general, aggressive polychemotherapy regimens are
recommended in these neoplasms of plasmacytoid dendritic
cells and other rare unclassified CL, although no large studies
or therapeutic comparisons are available.
follow-up
The interval between visits for patients with CL must be
adjusted to the clinical findings. In those with early disease
(stage Ia, Ib), evaluation every 6–12 months is reasonable.
In advanced disease (stage III–IV), often the patient must
be checked every 4–6 weeks to assess the therapeutic
response.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
faculty.
Table 3. Therapy recommendations for lymphomatoid papulosis (level
of evidence III)
Degree of involvement First-line therapy Second-line therapy
Solitary or localized
lesions
Excision
Observation
Multifocal lesions Observation IFN
PUVA IFN + retinoid
Methotrexate
up to 20 mg/weekly
Bexarotene
Table 4. Therapy recommendations for large cell CD30+ C-ALCL (level
of evidence III)
Degree of involvement First-line therapy Second-line therapy
Solitary or localized
lesions
Excision Methotrexate
Radiation therapy IFN
Multifocal lesions
without spontaneous
remission
Methotrexate Radiation
therapy, IFN
Table 5. Therapy recommendations for Se´zary syndrome (level of
evidence IV)
First-line therapy Second-line therapy
PUVA + IFN Bexarotene
Extracorporeal photopheresis Chlorambucil/corticosteroids
HN2 Low-dose methotrexate
CHOP polychemotherapy
Denileukin–diftitox
Vorinostat
Total skin electron beam therapy
Table 6. Therapy recommendations for low-grade primary cutaneous B-
cell lymphoma (follicular lymphoma, marginal zone lymphoma) (level of
evidence IV)
Degree of
involvement
First-line therapy Second-line therapy
Solitary lesions Excision Intralesional
Antibiotics (only
in PCMZL)
Intralesional
corticosteroids
Radiation therapy
Multiple lesions Antibiotics (only
in PCMZL)
Intralesional IFN-a
Radiation therapy Intralesional rituximab
i.v. rituximab
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